Skip to content

Clinical-MRI Evaluation in Patients Undergoing Subtalar Arthrorisis With Reabsorbable Endorthesis Implant in PLLA

Clinical-MRI Evaluation in Patients Undergoing Subtalar Arthrorisis With Resorbable PLLA Endothesis Implant: Prospective Observational Study at 5 Years of Minimum Follow-up

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06525532
Acronym
CS-RM
Enrollment
35
Registered
2024-07-29
Start date
2024-06-12
Completion date
2026-12-31
Last updated
2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Limb Deformity

Keywords

arthrorrhesis, reabsorbable endorthotic implant, subtalar joint, pediatric joint implant

Brief summary

From the archives of the IRCCS Rizzoli Orthopedic Institute, all cases of arthrorrhesis of the subtalar joint with a reabsorbable endorthotic implant in PLLA will be retrieved. An overall electronic database will be created and all medical records of these cases will be reviewed. The eligibility of each individual patient will be assessed on the basis of the exclusion and inclusion criteria (non-probability convenience sampling). The study will not present a control group or comparison groups between therapeutic procedures.

Interventions

OTHERfollow up

performing a 3 Tesla MRI of the operated foot

Sponsors

Istituto Ortopedico Rizzoli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

* Age between 8 and 15 years at the time of surgery * Arthrorrhosis of the subtalar with reabsorbable endorthotic implant in PLLA * Minimum follow-up of 5 years

Exclusion criteria

* Revisions/explantation of the endorthesis device * Patients with active acute or chronic infections * Patients with chronic inflammatory joint diseases * Patients with previous significant trauma of the lower limbs following surgery * Patients with pre-existing anomalies of ambulatory kinematics (amputations, neuro-muscular diseases, poliomyelitis, hip dysplasias) * Patients with cognitive deficits * \- Patients with concomitant neurological pathologies * Patients suffering from tumor pathology * Patients with cardiac pacemakers or other prostheses equipped with electronic circuits * Patients with intracranial metal implants, metal heart valves, vascular clips, ferromagnetic endovascular filters/stents/coils, Swan-Ganz catheters or in any case positioned close to vital anatomical structures * Patients with orthopedic metal prostheses * Patients with cochlear implants or fixed hearing aids, lens prostheses with ferromagnetic intra-ocular points, IUD (coil) or splinters made of ferromagnetic material * Pregnant patients * Patients with insulin pumps and non-removable contact lenses

Design outcomes

Primary

MeasureTime frameDescription
Instrumental evaluationAt baseline (Day 0)Instrumental evaluation with 3 Tesla MRI of the degradation and possible resorption of the implant
evaluation of screw resorptionat baselineClinical and Magnetic Resonance Imaging Results - PMC (nih.gov), Poly-L-lactic acid - hydroxyapatite (PLLA-HA) bioabsorbable interference screws for tibial graft fixation in anterior cruciate ligament (ACL) reconstruction surgery

Secondary

MeasureTime frameDescription
clinical evaluation - Ankle-Hindfoot scoreat baseline (day 0)AOFAS: this questionnaire consists of points assigned to nine items divided into three categories: pain (40 points), functional aspects (50 points) and alignment (10 points) for a total of 100 points, the extreme of which represents a normal foot complex -ankle
Quality of life - SF-12at baselineThe SF-12 health questionnaire is a standardized generic instrument for the rapid, economical and disease-free acquisition of the patient's health-related quality of life.

Countries

Italy

Contacts

Primary ContactMassimiliano Mosca, MD
massimiliano.mosca@ior.it0516366
Backup ContactSilvio Caravelli, PhD
silvio.caravelli@ior.it0516366

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026